Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is set to announce its earnings results after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of $2.53 per share for the quarter. Jazz Pharmaceuticals PLC has set its FY17 guidance at $10.70-11.30 EPS.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.85 by ($0.13). The business had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same period last year, the company posted $2.67 earnings per share. On average, analysts expect Jazz Pharmaceuticals PLC to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at $137.89 on Friday. The stock has a market capitalization of $8,285.95, a P/E ratio of 19.15, a P/E/G ratio of 0.83 and a beta of 1.00. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $163.75. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.65 and a quick ratio of 2.49.

Several equities analysts recently issued reports on JAZZ shares. Cowen and Company reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Friday, July 14th. Piper Jaffray Companies set a $182.00 price target on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a report on Friday, July 14th. Deutsche Bank AG set a $178.00 price target on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a report on Monday, July 17th. BidaskClub cut Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Finally, Zacks Investment Research raised Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $174.00 price target on the stock in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have assigned a buy rating to the stock. Jazz Pharmaceuticals PLC has a consensus rating of “Buy” and an average target price of $180.88.

In other Jazz Pharmaceuticals PLC news, Director Patrick G. Enright sold 351 shares of the stock in a transaction on Friday, August 25th. The stock was sold at an average price of $148.40, for a total value of $52,088.40. Following the completion of the sale, the director now owns 1,717 shares in the company, valued at approximately $254,802.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $150.00, for a total value of $150,000.00. The disclosure for this sale can be found here. Insiders sold a total of 4,517 shares of company stock valued at $665,623 in the last quarter. 4.30% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Jazz Pharmaceuticals PLC (JAZZ) Set to Announce Quarterly Earnings on Tuesday” was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.watchlistnews.com/jazz-pharmaceuticals-plc-jazz-set-to-announce-quarterly-earnings-on-tuesday/1680108.html.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Earnings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.